"Eosinophils" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Granular leukocytes with a nucleus that usually has two lobes connected by a slender thread of chromatin, and cytoplasm containing coarse, round granules that are uniform in size and stainable by eosin.
| Descriptor ID |
D004804
|
| MeSH Number(s) |
A11.118.637.415.345 A11.627.340.345 A15.145.229.637.415.345 A15.382.490.315.251
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Eosinophils".
Below are MeSH descriptors whose meaning is more specific than "Eosinophils".
This graph shows the total number of publications written about "Eosinophils" by people in this website by year, and whether "Eosinophils" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 0 | 1 |
| 2002 | 1 | 1 | 2 |
| 2004 | 1 | 0 | 1 |
| 2005 | 1 | 2 | 3 |
| 2006 | 0 | 2 | 2 |
| 2007 | 1 | 2 | 3 |
| 2008 | 3 | 1 | 4 |
| 2009 | 2 | 1 | 3 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 1 | 2 | 3 |
| 2013 | 4 | 2 | 6 |
| 2014 | 0 | 1 | 1 |
| 2015 | 0 | 1 | 1 |
| 2016 | 1 | 3 | 4 |
| 2017 | 4 | 0 | 4 |
| 2018 | 1 | 1 | 2 |
| 2019 | 5 | 2 | 7 |
| 2020 | 1 | 6 | 7 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 1 | 1 |
| 2023 | 1 | 4 | 5 |
| 2024 | 3 | 0 | 3 |
| 2025 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Eosinophils" by people in Profiles.
-
N-acetyl-L-alanine ameliorates atopic dermatitis-like symptoms by suppressing Th2 differentiation in DNFB-induced NC/Nga mice. BMB Rep. 2025 Oct; 58(10):437-443.
-
Type 2 inflammation biomarkers and their association with response to dupilumab in COPD (BOREAS): an analysis of a randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Aug; 13(8):687-697.
-
Peripheral eosinophil count as a biomarker for asthma exacerbation severity in acute care settings. Ann Allergy Asthma Immunol. 2025 Jul; 135(1):63-70.e3.
-
Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials. Lancet Respir Med. 2025 Jun; 13(6):505-516.
-
Estrogen signaling suppresses tumor-associated tissue eosinophilia to promote breast tumor growth. Sci Adv. 2024 Sep 27; 10(39):eadp2442.
-
Mucosal-associated invariant T cells modulate innate immune cells and inhibit colon cancer growth. Scand J Immunol. 2024 Sep; 100(3):e13391.
-
Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation. N Engl J Med. 2024 06 27; 390(24):2274-2283.
-
Lebrikizumab in Uncontrolled Asthma: Reanalysis in a Well-Defined Type 2 Population. J Allergy Clin Immunol Pract. 2024 May; 12(5):1215-1224.e3.
-
Determination of Optimal Eosinophil Thresholds for Diagnosis of Eosinophilic Gastritis and Duodenitis: A Pooled Analysis of 4 Prospective Studies. Clin Transl Gastroenterol. 2024 Jan 01; 15(1):e00656.
-
Tezepelumab in patients with allergic and eosinophilic asthma. Allergy. 2024 05; 79(5):1134-1145.